DecisionView Launches StudyOptimizer 4
San Francisco, CA – December 10, 2009
DecisionView Inc., a provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer™ 4, the latest iteration of its Web-based solution. DecisionView’s flagship product now includes advanced historical analysis and templates capabilities, as well as enhancements to its predictive analytics technology.
StudyOptimizer allows clinical trial managers to plan, track, diagnose, and correct enrollment plans via a single centralized Web-based application that
captures clinical trial patient enrollment data from across the organization. The application uses predictive analytics to forecast enrollment trends and estimate completion dates, which are updated based on actual enrollment patterns giving clinical trial managers information to measure actual and projected performance against plan.
“The ability to capture, analyze, and leverage historical clinical trial enrollment data in planning future patient recruitment efforts provides a critical baseline that life sciences organizations need in order to benchmark and improve these processes,” said said Alan Louie, Ph.D., Research Director, IDC.
Recently, DecisionView announced the availability of the Software-as-a-Service (SaaS) version of StudyOptimizer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
